Trial Profile
A study to evaluate the ability of the HM74A agonist GSK256073A to block niacin-induced flushing in healthy adult subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 256073 (Primary)
- Indications Flushing
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 18 Aug 2008 Actual study completion date is 1 May 2008 as reported by ClinicalTrials.gov.
- 18 Aug 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.